Epirubicin Hydrochloride

Acute leukemia and malignant lymphoma, breast cancer, bronchial lung cancer, ovarian cancer, Wilms tumor, soft tissue sarcoma, bladder cancer, testicular cancer, prostate cancer, gastric cancer, liver cancer (including primary hepatocellular carcinoma and metastatic cancer) and medullary thyroid cancer and other solid tumors.

For intravenous or intra-arterial injection, add normal saline to dissolve to a concentration of 2mg/m1 before use. For intravenous drip, add 100ml~250ml normal saline for drip. The common dosage for adults is 50mg~70mg/m2 per course of treatment based on body surface area. It can be given once, or divided equally on the 1st and 8th day, and repeated after 3 to 4 weeks (intracavitary chemotherapy can be repeated after 2 to 3 weeks). For combined chemotherapy, 2/3 of a single dose can generally be used. The total dose should not exceed 700mg/m2, and the dosage for children is about 1/3 to 1/2 of the adult dose. For intraperitoneal chemotherapy, 60mg~80mg/time, combined with cisplatin and fluorouracil or mitomycin, especially large-volume intraperitoneal chemotherapy can improve the efficacy. For intra-arterial administration, 60mg~80mg/time, it is also advisable to combine drugs, especially with cisplatin, once/1 month to 3 months. Intrathoracic or intrabladder administration, 50mg~60mg/time. The former can be used with cisplatin, but gastrointestinal reactions are significantly increased. Most of them need to be given intravenously before medication to avoid nausea and vomiting that may occur immediately. Instructions for use: During intravenous infusion, the drug should be prevented from leaking out of the blood vessels to avoid tissue damage and necrosis. This product cannot be used in combination with heparin to prevent precipitation.

Myocardial toxicity is milder than that of rubicin, and its incidence and severity are proportional to the cumulative dose of this product. Delayed severe ejection heart failure mostly occurs half a year after medication or when the total dose exceeds 700 mg. Common symptoms include nausea, vomiting, stomatitis, esophagitis, leukopenia, and hair loss. Myocardial toxicity is occasionally seen, and one should be alert to the possibility of congestive heart failure, which may sometimes cause death. Stomach pain, diarrhea or pan-gastroenteritis, hyperuricemia, and kidney damage may also occur. Venous overflow may cause pain, tissue necrosis, and even fossa tissue inflammation. Inhibition of bone marrow hematopoietic function manifests as thrombocytopenia and leukocytopenia. There is delayed cardiotoxicity, and the average dose causing cardiotoxicity is 935 mg/m2, while that of doxorubicin is 468 mg/m2. Hair loss: It may occur in about 60-90% of cases, which is generally reversible. In men, beard growth may be inhibited. Mucositis: It generally manifests as gastritis with erosion, inflammation of the tongue and sublingual glands. Gastrointestinal reactions such as nausea, vomiting, diarrhea. Fever, chills, urticaria and allergic reactions may be seen in a few cases.